Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azaquinzole SCHEMBL29387769 | 1.00 | TAAR1 (1.00) | TAAR1CHRNA7HTR2AHTR2CHTR2B | |
| Azaquinzole SCHEMBL18863221 | 1.00 | TAAR1 (1.00) | TAAR1CHRNA7HTR2AHTR2CHTR2B | |
| SCHEMBL11192963 | 0.85 | TAAR1 (0.73) | TAAR1CHRNA7HTR2AHTR2CHTR2B | |
| SCHEMBL29980741 | 0.85 | TAAR1 (0.73) | TAAR1CHRNA7HTR2AHTR2CHTR2B | |
| SCHEMBL1307195 | 0.81 | TAAR1 (0.69) | TAAR1CHRNA7 | |
| Hydrochloric Acid SCHEMBL6422058 | 0.80 | TAAR1 (0.67) | TAAR1CHRNA7 | |
| SCHEMBL6161535 | 0.79 | CHRNA7 (0.66) | TAAR1CHRNA7HTR2C | |
| SCHEMBL31204632 | 0.79 | CHRNA7 (0.66) | TAAR1CHRNA7HTR2C | |
| SCHEMBL20053841 | 0.78 | TAAR1 (0.64) | TAAR1 | |
| SCHEMBL17552264 | 0.78 | TAAR1 (0.64) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612532-B1 | VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF | NEUROCRINE BIOSCIENCES INC (US) | 2023-12-13 | — | — | EP | claimed |
| US-20130289275-A1 | PROCESS FOR THE PREPARATION OF PRAZIQUANTEL | SEQUENT SCIENTIFIC LIMITED (IN) | 2013-10-31 | — | — | US | claimed |
| EP-4691560-A2 | VMAT2 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-3612532-B1 | VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF | NEUROCRINE BIOSCIENCES INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | DICE MOLECULES SV, INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2022232380-A1 | PROCESSES FOR PREPARING A VMAT2 INHIBITOR | NEUROCRINE BIOSCIENCES, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| US-11040970-B2 | VMAT2 inhibitor compounds and compositions thereof | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| WO-2020163554-A1 | IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247785-A1 | IL-17 Ligands And Uses Thereof | DICE MOLECULES SV, INC. | 2020-08-06 | — | — | US | disclosed |
| US-20200131173-A1 | VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF | NEUROCRINE BIOSCIENCES, INC. | 2020-04-30 | — | — | US | disclosed |
| US-8754215-B2 | Process for the preparation of praziquantel | SEQUENT SCIENTIFIC LIMITED (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130289275-A1 | PROCESS FOR THE PREPARATION OF PRAZIQUANTEL | SEQUENT SCIENTIFIC LIMITED (IN) | 2013-10-31 | — | — | US | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2423207-A2 | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| US-3993759-A | 2-BENZOYL-4-OXO-1,2,3,6,7,11B-HEXAHYDRO-4H-PYRAZINO(2,1 -A)ISOQUINOLINE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | IL17A, IL2, IL15 | TAAR1 3270/4885CHRNA7 2165/4885HTR2A 4709/4885 |
| US-20200131173-A1 | VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF | SLC18A2, SLC6A2, SLC18A3 | TAAR1 241/4885CHRNA7 329/4885HTR2A 93/4885 |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MAPT, PRMT1, PSEN1 | TAAR1 805/4885CHRNA7 752/4885HTR2A 1196/4885 |
| US-11040970-B2 | VMAT2 inhibitor compounds and compositions thereof | SLC18A2, SLC6A2, SLC18A3 | TAAR1 241/4885CHRNA7 329/4885HTR2A 93/4885 |
| US-20200247785-A1 | IL-17 Ligands And Uses Thereof | IL17A, IL2, IL15 | TAAR1 3270/4885CHRNA7 2165/4885HTR2A 4709/4885 |
| US-20130289275-A1 | PROCESS FOR THE PREPARATION OF PRAZIQUANTEL | CYP4B1, CYP2E1, CYP1A2 | TAAR1 3051/4885CHRNA7 1296/4885HTR2A 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.